Crossmark

The combination of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis

Crossref DOI link: https://doi.org/10.1007/s00592-026-02666-9

Published Online: 2026-02-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Avogaro, Angelo https://orcid.org/0000-0002-1177-0516
Neccia, Matteo

Delfini, Marina

Franculli, Aldo

Enea, Giulia

Magli, Anna

Bemporad, Joshua

Fadini, Gian Paolo
Funding

Funding for this research was provided by:

Università degli Studi di Padova
License Information

Text and Data Mining valid from 2026-02-18

Version of Record valid from 2026-02-18
More Information

Article History

Received: 5 December 2025

Accepted: 29 January 2026

First Online: 18 February 2026

Declarations

:

: AA received honoraria for speaker activities, for serving on advisory boards, or consultancy from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Amarin, Bruno Farmaceutici, Amgen, Novo Nordisk, and Sanofi. GPF received honoraria for speaker activities, for serving on advisory boards, or consultancy from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Guidotti, Novartis, Novo Nordisk, and Sanofi. MN, MD, AF, GE, AM, and JB declare no Conflicts.

Document is current

Any future updates will be listed below